Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary
Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied
will diminish epistaxis in patients with HHT as measured by the HHT Epistaxis Severity Score
(ESS), hematocrit, and hemoglobin and serum ferritin levels.